A Phase 1/2 interventional study of Acne mRNA vaccine and Placebo in Acne, sponsored by Sanofi Pasteur, a Sanofi Company. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-09.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 373 studies in Acne Vulgaris with a site in United States — 19 open to participants now, 28 under way, 2 of them phase 3. Acne Vulgaris · United States.
Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 116th largest by planned enrollment of the 353 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 1/2, reaches primary completion later than 27 of the 27 other live ones, and was the 364th registered.
792 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →19 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:
Sagimet Biosciences Inc. · Sites in United States
Ages 12+
Integrative Skin Science and Research · Sites in United States
Ages 9+ · Healthy volunteers
Bausch Health Americas, Inc. · Sites in United States
Ages 9–11
Sagimet Biosciences Inc. · Sites in United States, Australia
Ages 18–55 · Healthy volunteers
Medical University of South Carolina · Sites in United States
Ages 12+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Acne Vulgaris studies recruiting now, 15 (33%) set no upper age limit and 29 (64%) stop at 75 or younger; 20 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
373 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 82 · Phase 3 82 · Phase 4 72
First in 2002; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 228 is above the median of 70 across 674 interventional studies indexed under Acne Vulgaris.
Median enrollment 78 across the 353 interventional studies, 59 across the 19 observational. Of the 323 that completed or were terminated, 189 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 373 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
Sanofi has 6 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
9 of the studies in Acne Vulgaris with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863193Phase 3Sagimet Biosciences Inc.Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA) | 2027-08 |
| NCT06315166PollogenStudy on Using Radiofrequency to Treat Moderate to Severe Acne | 2026-12 |
| NCT02713607University of California, DavisLipidome and Microbiome Profile of Acne | 2027-01 |
| NCT06989840Sagimet Biosciences Inc.Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne | 2027-01 |
| NCT07896486Weill Medical College of Cornell UniversityEvaluating a Brightening Serum for Post-Inflammatory Hyperpigmentation | 2027-01-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 373 studies in Acne Vulgaris with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extension (LTE). Core Study will include a Sentinel Cohort and a Main Cohort, with the Sentinel Cohort assessing the safety in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long term effects of the vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of mild facial acne vulgaris with:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 Acne mRNA Vaccine injections
Biological: Acne mRNA vaccine
Participants will receive 2 Placebo injections
Other: Placebo
Participants will receive 2 Acne mRNA Vaccine injections
Biological: Acne mRNA vaccine
Participants will receive 2 Placebo injections
Other: Placebo
Pharmaceutical form: suspension for injection Route of administration: intramuscular
Pharmaceutical form: liquid solution for injection Route of administration: intramuscular
Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with unsolicited systemic adverse events (AEs)
Time frame: In 30 minutes after each administration
Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with solicited injection site and systemic reactions
pre-listed in the participant diary \[PDi\] and in the case report form \[CRF\]
Time frame: Up to 7 days after each administration
Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with unsolicited AEs reported
Time frame: Up to 28 days after each administration
Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with medically attended adverse events (MAAEs)
Time frame: Up to 6 months after each administration
Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with AEs of special interest (AESIs)
Time frame: Up to 6 months after each administration
Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with serious AEs (SAEs)
Presence of all SAEs
Time frame: Up to 6 months after each administration
Core Study - Sentinel Cohort Arm 1 and 2: Number of participants with out-of-range biological test results
Presence of out-of-range biological test results (including shift from baseline values)
Time frame: Through 7 days after administration (Day 08)
Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of inflammatory acne lesions on face
Time frame: At 2 months post last administration
Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of non-inflammatory acne lesions on face
Time frame: At 2 months post last administration
Long-Term Extension - Sentinel and Main Cohort Arm 1 and 2: Number of participants with serious adverse events (SAEs) and adverse events of special interest (AESIs)
Presence of all SAEs and AESIs
Time frame: Up to 38 months after first administration
Core Study - Sentinel and Main Cohort Arm 1 and 2: Vaccine-antigen-specific serum antibody titers
Time frame: From baseline (Day 01) to 6 months post last administration
Core Study - Main Cohort Arm 1 and 2: Absolute change from baseline (Day 01) in the number of inflammatory acne lesions on face
Time frame: At 1 month post first administration to 6 months post last administration
Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of inflammatory acne lesions on face
Time frame: At 1 month post first administration to 6 months post last administration
Core Study - Main Cohort Arm 1 and 2: Absolute change from baseline (Day 01) in the number of non-inflammatory acne lesions on face
Time frame: At 1 month post first administration to 6 months post last administration
Core Study - Main Cohort Arm 1 and 2: Percentage change from baseline (Day 01) in the number of non-inflammatory acne lesions on face
Time frame: At 1 month post first administration to 6 months post last administration
Core Study - Main Cohort Arm 1 and 2: Number of participants with unsolicited systemic adverse events (AEs)
Time frame: In 30 minutes after each administration
Core Study - Main Cohort Arm 1 and 2: Number of participants with solicited injection site and systemic reactions
pre-listed in the participant diary \[PDi\] and in the case report form \[CRF\]
Time frame: Up to 7 days after each administration
Core Study - Main Cohort Arm 1 and 2: Number of participants with unsolicited AEs reported
Time frame: Up to 28 days after each administration
Core Study - Main Cohort Arm 1 and 2: Number of participants with medically attended adverse events (MAAEs)
Time frame: Up to 6 months after each administration
Core Study - Main Cohort Arm 1 and 2: Number of participants with AEs of special interest (AESIs)
Time frame: Up to 6 months after each administration
Core Study - Main Cohort Arm 1 and 2: Number of participants with serious AEs (SAEs)
Presence of all SAEs
Time frame: Up to 6 months after each administration
Core Study - Main Cohort Arm 1 and 2: Number of participants with out-of-range biological test results
Presence of out-of-range biological test results (including shift from baseline values)
Time frame: Through 7 days after administration (Day 08)
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Jul 2025 (actual). Primary completion is estimated for Jun 2029, 47 months after the start.
Of 13 phase 1/2 interventional studies under Acne Vulgaris, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's planned 47 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanofi Pasteur, a Sanofi Company →